ArticleOpen life sciences2026
KRT16 and APOA1: key regulators of proliferation and lipid metabolism in non-small cell lung cancer.
Article in Open life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to analyze the biological function of KRT16 and its interaction mechanism with apolipoprotein A1 (APOA1) in Non-Small Cell Lung Cancer (NSCLC). KRT16 expression and prognostic value in NSCLC were analyzed using the TCGA, GEPIA, and STRING databases. Functional impacts were assessed in A549 cells transfected with shKRT16 or APOA1 overexpression vectors. Gene/protein expression (RT-qPCR, Western blot), proliferation (MTT, EdU), cell cycle/apoptosis (flow cytometry), migration/invasion (Transwell), and lipid droplet accumulation (Oil Red O, Nile Red staining) were evaluated. The KRT16-APOA1 interaction was verified by co-immunoprecipitation, immunofluorescence, and GST pull-down assays. In NSCLC, KRT16 was up-regulated, and its high levels were associated with advanced tumor stage, lymph node metastasis, and poor prognosis. KRT16 levels were significantly elevated in patients aged 21-40 and were associated with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.